Solid Biosciences to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced that its COO, Joel Schneider, PhD, will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET. A live webcast will be accessible on the Company’s investor relations website, with a replay available after the event. Solid Biosciences focuses on developing therapies for Duchenne muscular dystrophy, specifically targeting the underlying mutations with its lead gene therapy candidate, SGT-001.

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 3:30 p.m. ET.

A live webcast of this presentation will be available on the Company’s investor relations website, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the event.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com

FAQ

When is the Solid Biosciences presentation at the Jefferies Virtual Healthcare Conference?

The presentation is scheduled for June 3, 2021, at 3:30 p.m. ET.

Who will present for Solid Biosciences at the Jefferies Conference?

Joel Schneider, PhD, the Chief Operating Officer, will present.

Where can I watch the Solid Biosciences presentation?

The presentation will be available via a live webcast on the Company’s investor relations website.

What is Solid Biosciences' main focus?

The Company focuses on advancing therapies for Duchenne muscular dystrophy.

What is SGT-001 from Solid Biosciences?

SGT-001 is the Company's lead gene therapy candidate designed to address Duchenne at its core.